These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 7712445)
1. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15. Byhardt RW; Scott CB; Ettinger DS; Curran WJ; Doggett RL; Coughlin C; Scarantino C; Rotman M; Emami B Cancer; 1995 May; 75(9):2337-44. PubMed ID: 7712445 [TBL] [Abstract][Full Text] [Related]
2. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06. Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325 [TBL] [Abstract][Full Text] [Related]
3. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer. Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135 [TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596 [TBL] [Abstract][Full Text] [Related]
7. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Komaki R; Scott C; Ettinger D; Lee JS; Fossella FV; Curran W; Evans RF; Rubin P; Byhardt RW Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):149-55. PubMed ID: 9212017 [TBL] [Abstract][Full Text] [Related]
8. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112 [TBL] [Abstract][Full Text] [Related]
9. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Sause W; Kolesar P; Taylor S IV; Johnson D; Livingston R; Komaki R; Emami B; Curran W; Byhardt R; Dar AR; Turrisi A Chest; 2000 Feb; 117(2):358-64. PubMed ID: 10669675 [TBL] [Abstract][Full Text] [Related]
10. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942 [TBL] [Abstract][Full Text] [Related]
11. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group. Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer. Zwitter M; Kovac V; Smrdel U; Strojan P J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933 [TBL] [Abstract][Full Text] [Related]
14. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer. Ajlouni M; Chapman R; Kim JH Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551 [TBL] [Abstract][Full Text] [Related]
15. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128 [TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06. Lee JS; Scott C; Komaki R; Fossella FV; Dundas GS; McDonald S; Byhardt RW; Curran WJ J Clin Oncol; 1996 Apr; 14(4):1055-64. PubMed ID: 8648357 [TBL] [Abstract][Full Text] [Related]
17. Concurrent paclitaxel-cisplatin and twice-a-day irradiation in stage IIIA and IIIB NSCLC shows improvement in local control and survival with acceptable hematologic toxicity. Pisch J; Moskovitz T; Esik O; Homel P; Keller S Pathol Oncol Res; 2002; 8(3):163-9. PubMed ID: 12515995 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601). Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N; Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618 [TBL] [Abstract][Full Text] [Related]
20. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer. Blanke C; DeVore R; Shyr Y; Epstein B; Murray M; Hande K; Stewart S; Johnson D Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):111-6. PubMed ID: 9054884 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]